WO2010017403A3 - Therapeutic compositions, devices and methods for observing treated tissues - Google Patents

Therapeutic compositions, devices and methods for observing treated tissues Download PDF

Info

Publication number
WO2010017403A3
WO2010017403A3 PCT/US2009/053021 US2009053021W WO2010017403A3 WO 2010017403 A3 WO2010017403 A3 WO 2010017403A3 US 2009053021 W US2009053021 W US 2009053021W WO 2010017403 A3 WO2010017403 A3 WO 2010017403A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
methods
devices
human
immuno
Prior art date
Application number
PCT/US2009/053021
Other languages
French (fr)
Other versions
WO2010017403A2 (en
WO2010017403A9 (en
Inventor
Leonard S. Girsh
Original Assignee
Immunopath Profile, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunopath Profile, Inc. filed Critical Immunopath Profile, Inc.
Publication of WO2010017403A2 publication Critical patent/WO2010017403A2/en
Publication of WO2010017403A3 publication Critical patent/WO2010017403A3/en
Publication of WO2010017403A9 publication Critical patent/WO2010017403A9/en
Priority to US13/021,487 priority Critical patent/US20110213236A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

The present invention relates to a therapeutic composition and uses thereof for treatment of damaged tissue. The composition comprises at least one extracellular matrix compound, at least one polar surface active lipid, and a plurality of amino acids having a molar ratio which is characteristic of human breast milk protein. Composition therapeutics also comprises a plurality of amino acids having a molar ratio which is characteristic of human bowel protein and further comprises a fatty acid, gamma- amino butyric acid or L- carnitine. Using FDA approved-as-safe components equivalent to the components of human tissue, composition therapeutics is immunologically concordant with genetic 'self and the immuno-inflammatory barrier and thereby avoids crossing and activating the immuno- inflammatory barrier.
PCT/US2009/053021 2008-08-06 2009-08-06 Therapeutic compositions, devices and methods for observing treated tissues WO2010017403A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/021,487 US20110213236A1 (en) 2008-08-06 2011-02-04 Therapeutic compositions, devices and methods for observing treated tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8657408P 2008-08-06 2008-08-06
US61/086,574 2008-08-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/021,487 Continuation-In-Part US20110213236A1 (en) 2008-08-06 2011-02-04 Therapeutic compositions, devices and methods for observing treated tissues

Publications (3)

Publication Number Publication Date
WO2010017403A2 WO2010017403A2 (en) 2010-02-11
WO2010017403A3 true WO2010017403A3 (en) 2010-05-27
WO2010017403A9 WO2010017403A9 (en) 2010-11-04

Family

ID=41664204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/053021 WO2010017403A2 (en) 2008-08-06 2009-08-06 Therapeutic compositions, devices and methods for observing treated tissues

Country Status (1)

Country Link
WO (1) WO2010017403A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108710769A (en) * 2018-05-31 2018-10-26 湖北工业大学 The construction method of irregular sand grains model in a kind of emulation of discrete element
IL299488A (en) * 2020-07-02 2023-02-01 Univ Florida Formulations for promoting hydration and methods of use thereof
CN112394178B (en) * 2020-11-16 2022-08-05 首都医科大学附属北京朝阳医院 Biomarker and kit for moxifloxacin-related liver injury and application of biomarker and kit

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074051A1 (en) * 1999-08-17 2006-04-06 Girsh Leonard S Therapeutic stem cell growth factor composition, anti-inflammatory composition, and uses thereof
US20060241495A1 (en) * 2005-03-23 2006-10-26 Eastman Kodak Company Wound healing monitoring and treatment
US20070123961A1 (en) * 2004-11-12 2007-05-31 Asthmax, Inc. Energy delivery and illumination devices and methods
US20070141181A1 (en) * 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141181A1 (en) * 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20060074051A1 (en) * 1999-08-17 2006-04-06 Girsh Leonard S Therapeutic stem cell growth factor composition, anti-inflammatory composition, and uses thereof
US20070123961A1 (en) * 2004-11-12 2007-05-31 Asthmax, Inc. Energy delivery and illumination devices and methods
US20060241495A1 (en) * 2005-03-23 2006-10-26 Eastman Kodak Company Wound healing monitoring and treatment

Also Published As

Publication number Publication date
WO2010017403A2 (en) 2010-02-11
WO2010017403A9 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
US20230165915A1 (en) Materials and methods for improving immune responses and skin and/or mucosal barrier functions
WO2012081982A3 (en) Whey protein composition with a reduced astringency
BRPI1007379B8 (en) pharmaceutical compositions for the treatment or prevention of oral infections by e. coli
EP2450433A3 (en) Methods of preparing and using stem cell compositions and kits comprising the same
JP2009234980A (en) Cosmetic composition incorporating cell growth factor blended with neuraminic acids and placenta
WO2008137758A3 (en) Amino acid lipids and uses thereof
EA201101243A1 (en) 3H-IMIDAZO [4,5-C] PIRIDIN-6-CARBOXAMIDE AS ANTI-INFLAMMATORY MEANS
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
US20100221197A1 (en) Antimicrobial agent and external preparation for skin containing the same
WO2009087632A3 (en) Emulsified wax compositions and uses thereof
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2007136679A3 (en) Targeting vegf-b regulation of fatty acid transporters to modulate human diseases
BR112012006283A2 (en) stabilized adamts13 formulation, method for manufacturing a stabilized adamts13 formulation, kit, and methods for treating or preventing a disease and for treating or preventing a stroke
BR112019013106A2 (en) peptide to promote regeneration of dentin or dental pulp tissues, polynucleotide, expression vector, pharmaceutical composition, quasi-drug composition, healthy functional food composition, method of preventing or treating diseases of dentin or dental pulp and method of promote the regeneration of dentin tissues or dental pulp
GB2472379A (en) Topical cosmetic formulation comprising MSM, a vitamin and a carbohydrate
RU2015136674A (en) NUTRITIONAL COMPOSITIONS CONTAINING A PEPTIDE COMPONENT WITH THE ABILITY TO STIMULATE THE PRODUCTION OF ADIPONECTIN, AND THEIR APPLICATION
RU2668827C2 (en) Topical antimicrobial dermatological composition
WO2010049011A3 (en) Active-ingredient combination for treating mature skin ii
WO2010017403A3 (en) Therapeutic compositions, devices and methods for observing treated tissues
WO2012027690A1 (en) Control of biofilm formation
EP2578235A3 (en) Liquid formulation of G-CSF conjugate
US9962354B2 (en) Method and composition for bacterial or fungal suppression on skin
WO2010081800A3 (en) Hylauronic acid containing compositions for treatment of wounds, scars, post-surgical adhesion formation
JP2006219432A (en) Composition having rough skin-preventing activity, cosmetic and beverage
CN103054753B (en) Oil removal type cleansing foaming agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09805571

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09805571

Country of ref document: EP

Kind code of ref document: A2